|
|||||
|
|
Raves and risks for erythropoietin |
|
| Authors: | Maiese Kenneth Chong Zhao Zhong Shang Yan Chen |
| Affiliation: | aDivision of Cellular and Molecular Cerebral Ischemia, United States bDepartment of Neurology, United States cDepartment of Anatomy & Cell Biology, Center for Molecular Medicine and Genetics, Institute of Environmental Health Sciences, United States dBarbara Ann Karmanos Cancer Institute, 8C-1 UHC, 4201 St. Antoine, Wayne State University School of Medicine, Detroit, MI 48201, United States |
| Abstract: | Global use of erythropoietin (EPO) continues to increase as a proven agent for the treatment of anemia. Yet, EPO is no longer believed to have exclusive biological activity in the hematopoietic system and is now considered applicable for a variety of disorders such as diabetes, Alzheimer's disease, and cardiovascular disease. Treatment with EPO is considered to be robust and can prevent metabolic compromise, neuronal and vascular degeneration, and inflammatory cell activation. On the converse side, observations that EPO administration is not without risk have fueled controversy. Here we present recent advances that have elucidated a number of novel cellular pathways governed by EPO to open new therapeutic avenues for this agent and avert its potential deleterious effects. |
| Keywords: | Angiogenesis Cardiac Diabetes Erythropoietin Neurodegeneration |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |